interestingly they are having a decent run - mostly off the back of MSB momentum: There is definitely a trading strategy for someone who wants exposure to the prospects of the stem cell industry (MSB approval will float all boats) but doesn't want the full brunt of a potential CRL impact (upside will also not be as great as it will be for MSB, but will benefit nonetheless from MSBs success in that scenario).
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA, page-724
-
- There are more pages in this discussion • 373 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.02 |
Change
0.005(0.50%) |
Mkt cap ! $1.147B | |||
| Open | High | Low | Value | Volume |
| $1.02 | $1.02 | $1.00 | $1.101M | 1.092M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 19 | 48367 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.02 | 37418 | 24 |
View Market Depth
| Last trade - 13.13pm 19/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |